Use of antithymocyte globulin (rabbit) in a patient with known alpha-gal syndrome undergoing allogenic stem cell transplantation.
Hannah PetersonDrew A WellsDennis MarjoncuKori HolmanPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Due to the heterogeneity of AGS manifestations in patients, the use of rATG in patients with known AGS should be considered on a case-by-case basis. The administration of a test dose may help predict the occurrence of severe hypersensitivity reactions. The limited data surrounding the risk of AGS with rabbit-containing products and the various indications for the use of rATG warrants more in-depth study of the reactivity of this medication in this population.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- case report
- ejection fraction
- newly diagnosed
- chronic kidney disease
- risk assessment
- healthcare
- prognostic factors
- electronic health record
- single cell
- drug induced
- optical coherence tomography
- emergency department
- patient reported outcomes
- big data
- adverse drug